Search

A new laboratory study provides evidence about how advanced age can be protective against cancer — with implications for treating patients in different age groups.

… Wednesday, December 4, 2024 When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer . That’s because genetic mutations build up in cells over years and decades, and ultimately drive the development of cancer

A study of nearly 900 kidney cancer tumors has identified previously unknown biomarkers that correlate with better treatment responses to immunotherapy and targeted therapy.

… Monday, September 7, 2020 Summary An international team of investigators led by Memorial Sloan Kettering’s Robert Motzer has identified biological attributes of kidney cancer tumors that correlate with better responses to immunotherapies and targeted therapies. Treatments for kidney cancer have improved

On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to zenocutuzumab (Bizengri®), the first approved systemic therapy for patients with advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) fusion and pancreatic adenocarcinoma harboring a (NRG1) fusion.

… Thursday, February 6, 2025 Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist Alison Schram, MD , the drug demonstrated durable antitumor activity and met prespecified

As we approach the end of 2019, learn about some of the biggest advances in clinical research made this year at MSK.

… Thursday, December 12, 2019 In 2019, MSK clinical researchers made several major discoveries that will improve the treatment of cancer and guide the development of new therapies. Many of these studies were made possible by large and small philanthropic donations, which allow researchers to pursue innovative

Fourteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 14, 2025, as part of Memorial Sloan Kettering’s 46th annual academic convocation.

… Monday, May 12, 2025 On May 14, 2025, 14 new PhD scientists will officially receive their degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) . The graduates will receive their diplomas as part of the 46th annual academic convocation and commencement ceremony held at

Degrees were presented and awards were given at the 35th annual ceremony held on May 14.

… Friday, May 23, 2014 Summary Degrees were presented and awards were given at the 35th annual ceremony held on May 14. President and CEO Craig Thompson welcomes attendees to the 35th annual Academic Convocation ceremony and Commencement for students from the Louis V. Gerstner, Jr. Graduate School of Biomedical

Memorial Sloan Kettering Cancer Center (MSK) issued the following statement today regarding financial results for the six months ended June 30, 2023.

… Tuesday, August 15, 2023 Memorial Sloan Kettering Cancer Center (MSK) issued the following statement today regarding financial results for the six months ended June 30, 2023:    MSK’s financial performance for the six months ended June 30, 2023, demonstrated continued improvement in operating results

MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.

… Friday, September 6, 2024 When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS signaling pathways work together to spur the spread of cancer in lung adenocarcinoma

Several Memorial Sloan Kettering Cancer Center (MSK) physician-scientists have been recognized by the American Society of Clinical Oncology (ASCO).

… Thursday, May 30, 2024 Several Memorial Sloan Kettering Cancer Center (MSK) physician-scientists have been recognized by the American Society of Clinical Oncology (ASCO). Every year, ASCO recognizes individuals who have made significant contributions to ASCO, the practice of clinical oncology, people

Chemotherapy is a common treatment for acute myeloid leukemia, but patients often stop responding. Until now, not much was known about why.

… Friday, December 2, 2016 Summary Acute myeloid leukemia is usually treated with chemotherapy , but patients often stop responding to these drugs and develop resistance to them. Now MSK investigators are learning why that is the case. Highlights Acute myeloid leukemia is the most common acute leukemia